Ablynx quickly delivers on Novo Nordisk collaboration

November 30, 2016 News BioVox

Almost exactly one year after Ablynx announced its collaboration with Novo Nordisk, their research project for the Danish pharma giant has reached a discovery milestone. Ablynx is developing a multi-specific Nanobody construct for Novo, a drug that can bind multiple relevant disease targets in a single molecule. This first milestone triggers a €1 million payment to the Nanobody developer.

Dr Edwin Moses, CEO of Ablynx, commented: “Our proprietary Nanobody technology platform is ideally suited to develop multi-specific Nanobody candidates that address multiple targets in a single drug molecule. The achievement of our first milestone just one year after we entered into the collaboration with Novo Nordisk is an endorsement of the power of our platform to rapidly generate novel, potent drug candidates against disease targets which are difficult to address with other technologies. We are looking forward to further advancing the programme and the Nanobody potentially progressing towards clinical studies in 2018.”

Read all Ablynx news

Avatar photo

With a local focus and global reach, the news platform BioVox shares insights into the Benelux life sciences ecosystem with readers across the world. BioVox is an independent publisher, providing its community with quality content and first-row access to interesting breakthroughs and trends in biotech, medtech, agtech, pharma, and more. We shine a spotlight on the latest news and innovations from both our partners and community.

All posts

Subscribe to the BioVox newsletter